# **Supplementary Material**

# Rational design and synthesis of a Novel BODIPY-based probe for selective imaging of Tau Tangles in human iPSC-derived cortical neurons

Alessandro Soloperto, Deborah Quaglio, Paola Baiocco, Isabella Romeo, Mattia Mori, Matteo Ardini, Caterina Presutti, Ida Sannino, Silvia Ghirga, Antonia Iazzetti, Rodolfo Ippoliti, Giancarlo Ruocco, Bruno Botta, Francesca Ghirga, Silvia Di Angelantonio, Alberto Boffi

# 1. Additional computational data







Figure S1. Chemical structures of compounds BT2-BT8. (ChemDraw version 20.1.0.112 (112); PerkinElmer Inc)

MARKER	Estimated free energy of binding (kcal/mol)			
BT1	-9.71			
BT2	-11.60 (POSE 1)			
	-10.39 (POSE 2)			
BT3	-9.38			
BT4	-9.75			
BT5	-3.99			
BT6	-7.95			
BT7	-5.72			
BT8	-7.62 (POSE 1)			
	-2.51 (POSE 2)			

Table S1

**Table S1.** Predicted Binding affinity of compounds BT1-BT8.

#### 1.1 Docking complexes





**Figure S2.** Molecular docking of BT2 pose 1 against the crystallographic structure of the PHF6 fragment. (a) Side view of the molecule in the protein tunnel. (b) Diagonal view of the molecule in the protein tunnel. (PyMOL Software. The PyMOL Molecular Graphics System, Version 2.2.0 Schrödinger, LLC. URL:https://pymol.org/2/)



**Figure S3.** Molecular docking of BT2 pose 2 against the crystallographic structure of the PHF6 fragment. (a) Side view of the molecule in the protein tunnel. (b) Diagonal view of the molecule in the protein tunnel. (PyMOL Software. The PyMOL Molecular Graphics System, Version 2.2.0 Schrödinger, LLC. URL: https://pymol.org/2/)



**Figure S4.** Molecular docking of BT3 against the crystallographic structure of the PHF6 fragment. (a) Side view of the molecule in the protein tunnel. (b) Diagonal view of the molecule in the protein tunnel. (PyMOL Software. The PyMOL Molecular Graphics System, Version 2.2.0 Schrödinger, LLC. URL: https://pymol.org/2/)



**Figure S5.** Molecular docking of BT4 against the crystallographic structure of the PHF6 fragment. (a) Side view of the molecule in the protein tunnel. (b) Diagonal view of the molecule in the protein tunnel. (PyMOL Software. The PyMOL Molecular Graphics System, Version 2.2.0 Schrödinger, LLC. URL: https://pymol.org/2/)



**Figure S6.** Molecular docking of BT5 against the crystallographic structure of the PHF6 fragment. (a) Side view of the molecule in the protein tunnel. (b) Diagonal view of the molecule in the protein tunnel. (PyMOL Software. The PyMOL Molecular Graphics System, Version 2.2.0 Schrödinger, LLC. URL: https://pymol.org/2/)





**Figure S7.** Molecular docking of BT6 against the crystallographic structure of the PHF6 fragment. (a) Side view of the molecule in the protein tunnel. (b) Diagonal view of the molecule in the protein tunnel. (PyMOL Software. The PyMOL Molecular Graphics System, Version 2.2.0 Schrödinger, LLC. URL: https://pymol.org/2/)

# 

**Figure S8.** Molecular docking of BT7 against the crystallographic structure of the PHF6 fragment. (a) Side view of the molecule in the protein tunnel. (b) Diagonal view of the molecule in the protein tunnel. (PyMOL Software. The PyMOL Molecular Graphics System, Version 2.2.0 Schrödinger, LLC. URL: https://pymol.org/2/)



**Figure S9.** Molecular docking of neutral BT8 against the crystallographic structure of the PHF6 fragment: (a) Side view of the molecule in the protein tunnel. (b) Side view of the molecule protonated in the protein tunnel. (PyMOL Software. The PyMOL Molecular Graphics System, Version 2.2.0 Schrödinger, LLC. URL: https://pymol.org/2/)



**Figure S10.** Molecular docking of protonated BT8 against the crystallographic structure of the PHF6 fragment: (a) Side view of the molecule in the protein tunnel. (b) Side view of the molecule protonated in the protein tunnel. (PyMOL Software. The PyMOL Molecular Graphics System, Version 2.2.0 Schrödinger, LLC. URL: https://pymol.org/2/)



Figure S11. <sup>1</sup>H NMR Spectrum (CD<sub>2</sub>Cl<sub>2</sub>, 400 MHz) of compound 3. (created by MestReNova version 12.0.0-20080)



Figure S12. <sup>13</sup>C NMR Spectrum (CD<sub>2</sub>Cl<sub>2</sub>, 100 MHz) of compound 3. (created by MestReNova version 12.0.0-20080)

## 3. <sup>1</sup>H and <sup>13</sup>C NMR Spectra of BT1



Figure S13. <sup>1</sup>H NMR Spectrum (CD<sub>2</sub>Cl<sub>2</sub>, 400 MHz) of BT1. (MestReNova version 12.0.0-20080)



Figure S14. <sup>13</sup>C NMR Spectrum (CD<sub>2</sub>Cl<sub>2</sub>, 100 MHz) of BT1. (MestReNova version 12.0.0-20080)



Figure S15. ESI-MS Spectrum of compound 3.

## 5. ESI-MS Spectra of BT1

Figure S16



Figure S16. ESI-MS Spectrum of BT1.



#### Figure S17

Merge

Scale: 200 µm



#### 7. Emission spectra of TAU1

TAU1 probe (purity >95%) fluorescence was analyzed when TAU1 was dissolved at 10 mM in DMSO and then diluted in PBS buffer (pH 7.4) to reach at a final concentration of 100  $\mu$ M (1% DMSO) suitable for experiments with living neurons. Different excitation wavelengths, in the range 405- 640 nm, were selected and the corresponding emission spectra were recorded as shown in figure S18. Surprisingly, we found a very intense emission peak at 510 nm using as excitation wavelength 473 nm. As a possible explanation of this discrepancy with the previously reported spectra (ref Verwilst), in our experimental conditions TAU1 spectra were recorded in an aqueous solution and this may significantly affect the emission band if compared with an apolar solvent such as chloroform, which is not suitable for cell living (Hrdlovic et al., 2010).

#### Figure S18



**Figure S18.** Emission spectra of purchased probe Tau 1 (100  $\mu$ M) in PBS buffer pH 7.4 and 1 % DMSO according to the experimental conditions used for the immunostaining in human iPSC derived cortical neurons. The emission spectra were recorded at different  $\lambda$ ex as indicated in the legend on the right. (Ex. bandwidth = 10 nm; Em. bandwidth =10 nm). (GIMP software "The GIMP Development Team, 2019. GIMP, URL: https://www.gimp.org.)

#### Reference:

Hrdlovic P, Donovalova J, Stankovicova H, Gaplovsky A. Influence of polarity of solvents on the spectral properties of bichromophoric coumarins. Molecules. 2010;15(12):8915-8932

#### 8. Purification and fibrillogenesis assay of K18 domain of tau protein.

#### 8.1 Expression and purification of recombinant protein tau

Tau protein was designed from 244 to 376 amino acids and is referred to as the K18 domain which contains 4 microtubule-binding repeats (MTBR). K18 was expressed in E. coli BL-21 DE-3 strain and a high-density cell paste was purchased by Genscript Biotech Corporation<sup>®</sup>. Cell paste was homogenized and disrupted in a buffer containing (20 mM MES, 1 mM EDTA, 0,2 mM MgCl2, 300 mM NaCl, a tablet of cOmplete<sup>™</sup> Protease Inhibitor Cocktail (Sigma-Aldrich), and 2 mM TCEP (Tris(2-carboxyethyl)phosphine hydrochloride)). The suspension was sonicated using a sonicator at 40% amplitude with pulse 4s on and 10s off for 15 min. The lysate was heated at 80°C for 20 min, and then centrifuged at 12000 rpm. Next, the clear supernatant was dialysed against 20 mM MES, 50 mM NaCl, 1 mM EDTA, 1mM MgCl2 and applied to a HiPrep SP 16/10 cation exchange column (Cytiva) connected to a ÄKTApure 25 (Cytiva) and pre-equilibrated with the same buffer. Then, the column was washed, and the protein was eluted with a step gradient of NaCl (0.2 M–0.8 M). tau was found to elute at 0.25 M NaCl. The purified fractions were pooled and dialyzed in a PBS buffer and then concentrated using 3 kDa cut off protein centrifugal filters. Separation of the monomeric from the higher oligomers was performed by Size exclusion chromatography applying protein samples in PBS on a column HiLoad<sup>®</sup> 26/600 Superdex<sup>®</sup> 75 (Cytiva) equilibrated in the same buffer. The calibration curve was calculated by measuring the retention time of conventional standards including human ferritin (MW = 480 kDa), bovine serum albumin (MW = 60 kDa), and cytochrome C (MW = 14 kDa). The concentration of tau was determined by UV absorption at 270 nm using an extinction coefficient of  $\varepsilon$  = 1490 M-1 cm-1 with a Jasco V-750 (Jasco Corporation, Tokyo, Japan). Purified protein was stored at -80°C in small aliquots

#### 8.2 Transmission Electron Microscopy

The morphological characterization of tau fibrils has been carried out by bright-field transmission electron microscopy (TEM) using a CM100 electron microscope (Philips) equipped with high-contrast objective lens, a tungsten hexaboride (WB6) filament and a CMOS Phurona camera (Emsis). Micrographs have been acquired at 46000-130000X magnification while applying 100 keV electron energy on samples treated for negative staining as described herein. Two 20 µL drops of milliQ water and a 20 uL drop of 2% NanoW neutral stain solution (Ted Pella) have been placed on a piece of parafilm; 5 uL of sample solution have been placed onto the carbon surface of a 200 mesh carbon-coated copper grid (Ted Pella) gripped with the carbon-coated side facing up using negative locking tweezers and let to adsorb 30 s before blotting off the sample volume by touching the grid's edge with filter paper (Whatman); the sample has been then washed by touching the carbon-coated side with the water drop followed by blotting off with filter paper; for staining, the sample has been touched with the stain drop for 1 min before blotting off the stain solution with filter paper; a second washing step has carried out as described above and the grid has been air dried 20 min with the carbon-coated side facing up before TEM imaging.

#### Figure S19



**Figure S19.** TEM images of tau K18 protein incubated with heparin (ratio 1:1) at 37°C after 24 h, 48 h, 72 h confirming the formation of regular fibrils of tau.

#### 9. Reagents

#### Table S2

	Antibody name	Catalog number	Supplier	Dilution
	Anti-NeUN	PA578639	Therrmo Fisher Scientific	1:100
	Anti-HT7	MN1000	Therrmo Fisher Scientific	1:1000
	Anti-T22	ABN454	Merck Life Science	1:200
	Anti-AT8	MN1020	Therrmo Fisher Scientific	1:200
	Anti-TUJ1	T2200	Merck Life Science	1:1000
	Anti-MAP2	ab5392	Abcam	1:2000

Table S2. List of antibodies.

# Table S3

Primer name	Forward	Reverse	
NANOG	GAAATACCTCAGCCTCCAGC	GCGTCACACCATTGCTATTC	
PAX6	GCC CTC ACA AAC ACC TAC AG	TCA TAA CTC CGC CCA TTC AC	
NGN2	AAGACCCGTAGACTGAAGGC	GGTGAGTGCCCAGATGTAGT	
FOXG1	GTT CAC TTA CAG TCT GGT CCC	CCT GCC CTG TGA GTC TTT AAG	
TUJ1	TTT GGA CAT CTC TTC AGG CC	TTT CAC ACT CCT TCC GCA C	
MAP2	TTCCTCCATTCTCCCTCCTCGG	TCTTCCCTGCTCTGCGAATTGG	
SYNAPSIN1	CCC CAA TCA CAA AGA AAT GCT C	ATG TCC TGG AAG TCA TGC TG	
vGLUT1	TCA ATA ACA GCA CGA CCC AC	TCC TGG AAT CTG AGT GAC AAT G	

**Table S3.** List of primers used for evaluating the iPSC differentiation.